December 20, 2019
Launch of Joint Research with Asahi Kasei Pharma for the Discovery of Novel Small-Molecule Drugs Targeting mRNA
Veritas In Silico Inc. (Head Office: Shinagawa-ku, Tokyo; Representative Director: Shingo Nakamura) announced the launch of its joint research with Asahi Kasei Pharma (Head Office: Chiyoda-ku, Tokyo; President & Representative Director: Yoshikazu Aoki) for the discovery of novel small-molecule drugs targeting mRNA.
Please visit here for the details.
December 05, 2019
Principal Investigator Shino's poster presentation at the 37th Medicinal Chemistry Symposium
Amiu Shino, principal investigator at Veritas In Silico, gave a poster presentation entitled "RNA-targeted small-molecule drug discovery: screening and interaction analysis," during the 37th Medicinal Chemistry Symposium, which took place in Hachioji City, Tokyo on November 27-29, 2019.
Please visit here for the details of the 37th Medicinal Chemistry Symposium.
November 25, 2019
Senior Investigator Morishita's talk at the 7th NovAliX Conference
Ella Morishita, senior investigator at Veritas In Silico, gave an oral presentation during the 7th NovAliX Conference on Biophysics in Drug Discovery, which took place in Kyoto on November 13-15, 2019.
Please visit here for the details of the 7th NovAliX Conference.
November 5, 2019
Launch of Joint Research with Teijin Pharma for the Discovery of Novel Small-Molecule Drugs Targeting Nucleic Acids
Veritas In Silico Inc. ("VIS," Head Office: Shinagawa-ku, Tokyo; Representative Director: Shingo Nakamura) announced today the launch of its joint research with Teijin Pharma Limited ("Teijin Pharma," Head Office: Chiyoda-ku, Tokyo; President: Ichiro Watanabe), the core company of the Teijin Group's healthcare business, for the discovery of novel small-molecule drugs targeting nucleic acids.
Please visit here for the details.
September 6, 2019
Conclusion of Joint Research Agreement for the Discovery of Novel Small-Molecule Drugs Targeting Nucleic Acids
Nissan Chemical Corporation ("Nissan Chemical," Head Office: Chuo-ku, Tokyo; President: Kojiro Kinoshita) and Veritas In Silico Inc. ("VIS," Head Office: Shinagawa-ku, Tokyo; Representative Director: Shingo Nakamura) announce the conclusion of a joint research agreement for the discovery of novel small-molecule drugs that target nucleic acids.
Please visit here for the details.
December 12, 2018
Undisclosed joint research and development
CONTACT
Veritas In Silico Inc.
